119th Congress · introduced in the Senate · Apr 14, 2026
Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2026
Official title from Congress.gov
Latest action (Apr 14, 2026): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
4 citations.
INFECTIOUS DISEASES SOCIETY OF AMERICA · lobbying firm or registrant: ARENTFOX SCHIFF LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Budget/Appropriations
$50,000
Paid to lobbying firm
…ams dealing with infectious diseases generally H.R. 4445 (Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025), entire bill S.4283 (Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2026) H.R. 6500 (Continuing Appropriations and Extensions Act, 2027), regar…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INFECTIOUS DISEASES SOCIETY OF AMERICA · lobbying firm or registrant: INFECTIOUS DISEASES SOCIETY OF AMERICA
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Aug 7, 2026 · issue area: Medical/Disease Research/Clinical Labs
$290,000
Spent on own lobbying
…utive Orders regarding HHS, NIH, HRSA, FDA, and CDC, Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act (119th Congress, H.R. 4445/S.4283), SUPERBUGS Act, H.R.7879, 119th Congress.
Congress stated in the filing; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INFECTIOUS DISEASES SOCIETY OF AMERICA · lobbying firm or registrant: INFECTIOUS DISEASES SOCIETY OF AMERICA
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Aug 7, 2026 · issue area: Health Issues
$290,000
Spent on own lobbying
…Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445/S.4283 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation, J-1 Visa and Conrad 30 issues, H-1B Visa issues, 2026 CMS pr…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INFECTIOUS DISEASES SOCIETY OF AMERICA · lobbying firm or registrant: ARENTFOX SCHIFF LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 18, 2026 · issue area: Budget/Appropriations
$50,000
Paid to lobbying firm
…ams dealing with infectious diseases generally H.R. 4445 (Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2025), entire bill S.4283 (Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act of 2026)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing